HIV Treatment Bulletin - August / September 2003
Reports by Simon Collins, Polly Clayden, Graham McKerrow and Steve Taylor for HIV i-Base

Focusing on limitations of standard genotype analysis, Kearney and colleagues from NIH/NIAID also used single genome sequencing (SGS) to test the reliability for detecting minority populations.

They tested samples from 24 patients, either failing therapy or known to be infected with multi-drug resistant virus, by both standard and SGS and analysed with reference to the Stanford database.

All mutations present in composite genotype were detected by SGS. However, mutations present in <10% of single genomes, with one exception, were not detected by composite genotype. Mutations present in 10%-35% of single genomes were only detected in 25% of composite genotypes.

Several cases indicate the breadth of the missed mutations. Case one included 10 mutations conferring resistance to RTI, NNRTI and PI classes, but only present on 5-20% of the 20 genomes analysed. None of the PI mutations present in 15% of the genomes was detected by composite sequence including L10V, M46I, I84V and L90M.

A second sample missed five linked RT mutations present in 33% of genomes including K101E, Y181C, G190A and T215Y.

A third sample missed D67N in 30% of genomes and V118I present in 21%. All plasma samples contained at least one mutation that was identified by SGS but not by composite testing.

Comment

While these data appear alarming it is important to know that when a patient is on drugs and has truly developed resistance to these drugs with a documented rise in viral load the resistance mutations will generally be in excess of 50% of the total population and therefore will be picked up. However, once the selective pressure of the drug is removed their percentage in the viral population will fall quickly. Hence the rationale for obtaining the plasma sample for resistance testing while the patient is still taking the suspect drug.

Ref: Kearney M et al - Comparison of single-genome sequencing with standard genotype analysis for detection of HIV-1 drug-resistance mutations. Antiviral Therapy 2003; 8:S96 (Abstract 86).

030810
IB30407-05

©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.